anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
OBJECTIVE: To evaluate maternal and neonatal outcomes by type of antihypertensive used in participants of the CHAP (Chronic Hypertension in Pregnancy) trial.
METHODS: We conducted a planned secondary analysis of CHAP, an open-label, multicenter, randomized trial of antihypertensive treatment compared with standard care (no treatment unless severe hypertension developed) in pregnant patients with mild chronic hypertension (blood pressure 140-159/90-104 mm Hg before 20 weeks of gestation) and singleton pregnancies. We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compared with standard care, and labetalol compared with nifedipine. Although active compared with standard care groups were randomized, medication assignment within the active treatment group was not random but based on clinician or patient preference. The primary outcome was the occurrence of superimposed preeclampsia with severe features, preterm birth before 35 weeks of gestation, placental abruption, or fetal or neonatal death. The key secondary outcome was small for gestational age (SGA) neonates. We also compared medication adverse effects between groups. Relative risks (RRs) and 95% CIs were estimated with log binomial regression to adjust for confounding.
RESULTS: Of 2,292 participants analyzed, 720 (31.4%) received labetalol, 417 (18.2%) received nifedipine, and 1,155 (50.4%) received no treatment. The mean gestational age at enrollment was 10.5±3.7 weeks; nearly half of participants (47.5%) identified as non-Hispanic Black; and 44.5% used aspirin. The primary outcome occurred in 217 (30.1%), 130 (31.2%), and 427 (37.0%) in the labetalol, nifedipine, and standard care groups, respectively. Risk of the primary outcome was lower among those receiving treatment (labetalol use vs standard adjusted RR 0.82, 95% CI, 0.72-0.94; nifedipine use vs standard adjusted RR 0.84, 95% CI, 0.71-0.99), but there was no significant difference in risk when labetalol was compared with nifedipine (adjusted RR 0.98, 95% CI, 0.82-1.18). There were no significant differences in SGA or serious adverse events between participants receiving labetalol and those receiving nifedipine.
CONCLUSION: No significant differences in predetermined maternal or neonatal outcomes were detected on the basis of the use of labetalol or nifedipine for treatment of chronic hypertension in pregnancy.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02299414.
BACKGROUND: Diarrhea is a leading cause of death among children <5 years of age and can have long-term adverse consequences for human development. The World Health Organization has recommended the therapeutic use of zinc for the treatment of diarrhea, along with oral rehydration solutions, since 2004. We studied recent trends in the use of zinc to treat diarrhea in 23 low- and middle-income countries.
METHODS: A repeated cross-sectional design of 46 Demographic and Health Surveys from 23 countries was used to estimate the average annual change in zinc treatment across recent years. The earlier surveys were conducted in different years from 2009 to 2014, and the latest surveys were conducted in different years from 2015 to 2023, with an average gap of 6 years between surveys. A diarrhea episode during the 2 weeks before the survey and the treatment of diarrhea using zinc and oral rehydration solutions among children <5 years old was identified using an interview with mothers.
RESULTS: In the pooled sample, the treatment of diarrhea in children <5 years of age using zinc increased from 2% in the earlier surveys to 27% in the more recent surveys, or an average annual increase of 4 percentage points (pp). The prevalence of zinc treatment increased in all 23 countries, ranging from 9 pp per year on average in Sierra Leone to 1 pp in Cambodia.
CONCLUSIONS: A large increase in the use of therapeutic zinc to treat diarrhea in children was observed in recent years. However, coverage remains incomplete.
The invention relates to a completely novel type of micro-capsules, viz. such capsules where an encapsulated hydrophobic or lipophilic substance is surrounded by polar solid crystals of polar lipids which expose their hydrophilic face outwards and their hydrophobic face turned inwards towards the hydrophobic or lipophilic substance. These micro-capsules can be utilized to encapsulate for instance tacky substances or substances to be protected against oxidation or influence from light. Moreover, an especially interesting use according to the invention is the use of said micro-capsules in an ointment base, where the active ingredient is well protected within said capsules up to the use but which at the application on the skin directly comes into contact with the skin surface as a consequence of the crystalline structure of the shell. Furthermore, the invention relates to a special micro-capsule composition in the form of a dispersion of said micro-capsules in water or a polar liquid, where the crystals constitute 5-50 percent by weight and water or the polar liquid 50-95 percent by weight. Moreover, the invention relates to a process for the preparation of said micro-capsules, wherein a mixture of said polar lipid with water or polar liquid is formed, the mixture is heated above the transition temperature of the lipid and the mixture is then cooled to the desired temperature so as to obtain crystallization, the hydrophobic or lipophilic substance being added before or during the liposomic phase. Finally, the invention relates to a crystal dispersion of the polar lipid in a polar liquid, such as glycerol, ethylene- or propylene glycol.
Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the control group, ePROMs will be collected 24 and 52 weeks after radical prostatectomy, but without triggering an alarm with subsequent measures - the control group will therefore receive treatment according to the current clinical routine.
The recommended starting dose of AndroGel is 5 g once daily (preferably in the morning) to clean, dry, intact skin of the shoulders and upper arms and/or abdomen (area of application should be limited to the area that will be covered by the patient's short sleeve t-shirt). AndroGel must not be applied to the genitals. AndroGel is supplied as either a pump or in individual packets. After applying the gel, the application site should be allowed to dry for a few minutes prior to dressing. Avoid fire, flames or smoking until the gel has dried since alcohol based products, including AndroGel, are flammable. Hands should be washed with soap and water after AndroGel has been applied. [see Warnings and Precautions (5.2, 5.10)].
BACKGROUND: The long non-coding RNA X-inactive specific transcript (XIST) plays a crucial role in transcriptional silencing of the X chromosome. Zinc finger E-box-binding homeobox 1 (ZEB1) is a transcription factor involved in epithelial-mesenchymal transition (EMT) regulation.
AIMS: This study aimed to investigate the impact of XIST on esophageal squamous cell carcinoma (ESCC) progression and its underlying mechanism involving the miR-34a/ZEB1/E-cadherin/EMT pathway.
METHODS: XIST and ZEB1 expression were analyzed using quantitative PCR and immunohistochemistry. XIST knockdown was achieved in KYSE150 ESCC cells using siRNA or shRNA lentivirus transfection. Proliferation, migration, and invasion abilities were assessed, and luciferase reporter assays were performed to confirm XIST-miR-34a-ZEB1 interactions. In vivo ESCC growth was evaluated using a xenograft mouse model.
RESULTS: XIST and ZEB1 were upregulated in tumor tissues, correlating with metastasis and reduced survival. XIST knockdown inhibited proliferation, migration, and invasion of KYSE150 cells. It decreased ZEB1 expression, increased E-cadherin and miR-34a levels. Luciferase reporter assays confirmed miR-34a binding to XIST and ZEB1. XIST knockdown suppressed xenograft tumor growth.
CONCLUSION: XIST promotes ESCC progression via the miR-34a/ZEB1/E-cadherin/EMT pathway. Targeting the XIST/miR-34a/ZEB1 axis holds therapeutic potential and serves as a prognostic biomarker in ESCC.
The invention discloses a capsules of Chinese medicine treating cardiovascular and cerebral diseases and the making method, which is characterized in that: each kind of different Chinese herbal medicine is crushed before fully mixed according to certain weight proportion, thereby producing the capsule. Mixture ratio of each ingredient is as below: Chinese toona powder 60% to 70%, danshen root 6% to 10%, astragalus 6% to 10%, liquorice 8% to 15%, notoginseng 2% to 5%, gen-seng 2% to 5%, safflower 1% to 3%, peach kernel 1% to 3%. Drug of 0.2g is packed into each capsule, ten capsules is taken each time and three times a day. The cure rate of the capsule can reach 98% for symptoms such as coronary heart disease, arrhythmia, dyspnea chest discomfort, insufficient blood supply upon heart, angina pectoris, atrioventricular premature beat, myocardial infarction, cardiac dilatation, palpitation, heartbeat, retardation of heartbeat. The capsules of Chinese medicine has the advantages of obvious therapeutic effect, low price, no side effect and health care. The capsules of Chinese medicine can be taken for long term and belongs to drug of green environmental protection.
A substantially purified preparation containing one or more soluble iron-releasing monokines and a method of preparing and using same. The monokines is heat labile and is retained by ultrafiltration on a YM-10 membrane. Molecular exclusion chromatography of macrophage conditioned supernatant containing the monokine yields fractions in the 30,000 to 65,000 relative molecular weight range with iron-releasing activity. Kinetic studies show that the monokine is rapidly released from activated macrophages after triggering with bacterial endotoxin, reaching plateau levels within 2-4 hours. The response of cells to the monokine depends on both the dose of the monokine administered and the duration of its exposure. The iron-releasing monokine is distinct from other factors secrted by activated macrophages, such as a cytolytic factor and Respiratory Inhibition Factor which causes reversible lesions in the electron transport chain.
Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit, based on clinical and biological tolerance. Treatment will be continued for 12 months, unless a side effect would occur.
This will be a one year pilot/feasibility study, assessing the effects of fixed or self-titrated dosages of SATIVEX® (Δ9-tetrahydrocannabinol /cannabidiol combination in a buccal spray) on withdrawal from cannabis and craving among cannabis dependent subjects. Subjects in this study will undergo an 8-week double-blind, placebo-controlled trial. Subjects will be regular cannabis-users who are not currently seeking treatment for cannabis dependence. Subjects will participate in each of 8 conditions, lasting 5 weekdays each (an ABACADAE study design); four smoke as usual conditions (SAU) and four cannabis abstinence conditions. During each abstinence condition (B, C, D, E conditions), subjects will be allocated to one condition including self-titration of placebo, fixed dose of placebo, self-titration of SATIVEX (up to a max of 40 sprays per day, equal to 108mg THC) or fixed dose of SATIVEX (40 sprays per day). Each medication phase will be followed by a washout period where individuals will be requested to smoke cannabis as usual (A condition). The experimental conditions will be: type of SATIVEX® spray used (active vs placebo), and titration regimen (fixed or self-titrated). This pilot study will allow us to demonstrate the feasibility of our approach and to determine the sample size to use secondarily for a larger study. Our ultimate goal is to determine optimal conditions to use for a subsequent randomized controlled trial assessing the efficacy of SATIVEX® in treatment of Cannabis dependence among treatment-seeking subjects.
Capturing health benefits of physical exercise in a medically useful form can treat obesity, cardiovascular disease, type 2 diabetes and cancer. Endurance exercise causes browning of white adipose tissue (WAT), and increases metabolic function by activating peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1 alpha (PGC-1α), a transcriptional co-activator. Transgenic mice over-expressing PGC-1α in skeletal muscle are resistant to age-related obesity and diabetes, and have increased browning of WAT. Meteorin-like protein (Metrn1) is now identified as mediating the increased WAT browning by PGC-1α. Also, endurance exercise upregulates circulating Metrn1 levels in humans and mice. Exogenous administration of Metrn1 to mice on a high fat diet (HFD) recapitulates exercise-mediated effects in the absence of exercise: activates browning and thermogenic gene programs in WAT, increases energy expenditure, reduces body weight, increases glucose tolerance, and reduces fasting glucose level. Genes characteristic of brown fat cells upregulated by Metrnl include Ucp1, Prdm16 and Cidea.
Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
Randomized to standard care (original randomized clinical trial): All children, now 6-8 years old, who were treated using the standard of care at the time (normal temperature) were included in this arm. Infants' temperatures were monitored per standard of care. Most infants were cared for on an open wamer that was servo-controlled to normal body temperature (37 C) or in a standard bassinette.
The study will include the following phases - 1) Hygiene phase of 2 weeks; 2) Gingivitis induction phase with stent lasting up to 2 weeks; and 3) Resolution phase of 2 weeks.

The intervention will consist of cessation of oral hygiene versus an active control of oral hygiene with a fluoridated toothpaste. This study is a modification of classical experimental gingivitis model. The study will prospectively enroll subjects and assign a maxillary sextant to the intervention, while the other sextant will serve as control in a split-mouth design of localized experimental gingivitis, utilizing localized stent-induced biofilm overgrowth model (SIBO). The intervention, i.e. oral hygiene cessation will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues. The purpose of this study is to evaluate the effects of oral hygiene cessation in the gingival tissues by an innovative non-invasive microimaging technique, i.e. Optical coherence tomography (OCT).
A nonwoven material formed of bicomponent fibers may be used as a cosmetic cushion to hold cosmetic compositions, such as liquid foundation, in a housing for consumer use with an applicator. The use of bicomponent fibers may allow for the utilization of various natural or synthetic materials for the core and shell which may be adjusted for greatest compatibility with cosmetic compositions. Bicomponent fibers forming nonwoven materials may be a polyethylene terephthalate (PET) core/ polyethylene (PE) shell composition. This PET/PE composition may allow for maximum stability and chemical resistance in combination with aggressive chemical ingredients. Cosmetic cushions using these nonwoven materials may feel sensationally pleasing to the consumer and perform with the best quality throughout the lifetime of the product. The cosmetic cushion also may look aesthetically pleasing when filled or saturated with product.
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on PREXXARTAN and other agents that affect the RAS.

Do not coadminister aliskiren with PREXXARTAN in patients with diabetes. Avoid use of aliskiren with PREXXARTAN in patients with renal impairment (GFR < 60 mL/min).
Life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in POMBILITI-treated patients. In clinical trials, 43 (27%) POMBILITI-treated patients experienced hypersensitivity reactions, including 4 (3%) patients who reported severe hypersensitivity reactions and 4 (3%) additional patients who experienced anaphylaxis (fulfilling at least one of the Sampson criteria). Three of the 4 (2%) patients experiencing anaphylaxis discontinued from the trial [see Clinical Studies (14)]. Two of the 4 patients who experienced anaphylaxis developed high anti-cipaglucosidase alfa-atga antibody titers [see Clinical Pharmacology (12.6)]. Anaphylaxis signs and symptoms included dyspnea, rash, hypotension, bronchospasm, edema, pharyngeal edema, and tongue swelling. Symptoms of severe hypersensitivity reactions included urticaria, pruritus, and flushing.

Prior to POMBILITI administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during POMBILITI administration.

  * If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, POMBILITI should be discontinued immediately, and appropriate medical treatment should be initiated. The risks and benefits of readministering POMBILITI following severe hypersensitivity reaction (including anaphylaxis) should be considered. Patients may be rechallenged using slower infusion rates. In patients with severe hypersensitivity reaction, desensitization measures to POMBILITI may be considered. If the decision is made to readminister POMBILITI, ensure the patient tolerates the infusion. If the patient tolerates the infusion, the dosage (dose and/or the rate) may be increased to reach the approved recommended dosage.
  * If a mild or moderate hypersensitivity reaction occurs, the infusion rate may be slowed or temporarily stopped [see Dosage and Administration (2.3)].
1458019 Polymer solutions for treating metal surfaces H JANDOUREK 28 Nov 1973 [4 Dec 1972] 55220/73 Heading C3P [Also in Division B2] Compositions for treating metal (ion)-containing surfaces to improve adherence of polymeric materials thereto comprise a polar aliphatic alcohol having a b.p. in the range 50- 150‹ C. and, dissolved in the alcohol, a polymer having both hydrophilic and hydrophobic groups, which polymer is a reaction product of (a) polyacrylic acid or a copolymer of acrylic acid and 2-sulphoethylmethacrylate or acrylamide and (b) glycidyl methacrylate, the mol ratio of the polymerized acrylic acid to the glycidyl methacrylate being in the range from 0À1 : 1 to 1 : 0. Specified solvents are ethanol, propanol and butanol. The compositions are particularly useful as primers in dental restorative applications. Examples illustrate the preparation of the polymer component wherein an appropriate acrylic polymer or copolymer is reacted with glycidyl methacrylate. Where the copolymer includes sulpho-methacrylate units, these are present in ammonium salt form and, after the desired reaction with the glycidyl ester has been effected, the ammonium salt form is converted to the free sulpho form by treatment with an acidic ion-exchange resin. In examples, surfaces of bovine teeth are primed with compositions of the invention and treated with a restorative material comprising (a) the reaction product of a glycidyl ether of a polyhydric phenol and methacrylic acid and (b) fused silica filler, the restorative material being cured in 15 minutes.
Postoperative pain is generally a novel experience among paediatric patients. Topical anaesthetics, distraction procedures, and buffering of anaesthetic solutions have been used in reducing the postoperative pain. In this review, the authors assessed various modalities used to alleviate postoperative pain in children's dental treatment under general anaesthesia. Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocol were strictly adhered to in this systematic review. Specific keywords including postoperative pain, general anaesthesia, children, and dental extraction were used in the search for relevant randomized control trial studies in Web of Science, Scopus and PubMed, and included articles published until June 2021. From a total of 191 abstracts, 21 were reviewed. From the six studies with the usage of non-steroidal anti-inflammatory drugs (NSAIDs) alone or in combination with paracetamol, four observed that the preoperative use of NSAIDs alone or in combination was better than paracetamol alone, one discovered preoperative intravenous paracetamol was better than postoperative intravenous paracetamol, and the remaining study found no difference among various groups. Of two studies comparing the usage of non-steroidal anti-inflammatory drugs with opioid analgesics, one stated intravenous fentanyl in combination was better, while the other study found no difference among groups. The results obtained in this review can be utilized by physicians to control postoperative pain in children undergoing dental treatment under general anaesthesia.
Liver graft dysfunction can arise from many disease processes, which include biliary obstruction, rejection, infection and ischemia. Battery of tests, and at times empiric therapy, is necessary to obtain final diagnosis. This results in waste of time and medical resources that can lead to delay in care, which may ultimately translate to increase morbidity and mortality, as well as increase in cost.

In this protocol, the investigators propose utilization of interventional endoscopy for the diagnosis and treatment of liver graft dysfunction. Use of endoscopic ultrasound (EUS) with possible liver biopsy and cholangiography, and endoscopic retrograde cholangiopancreatography in one session may facilitate diagnosis and treatment. All patients enrolled in this protocol will undergo the same procedural protocol. The quality of care metrics in these patients (such as length of stay, cost, mortality, etc), will be compared to that of historical controls.
Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
Although rare, sensitivity to sodium sulfacetamide may occur. Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Hypersensitivity reactions may occur when a sulfonamide is readministered, irrespective of the route of administration. At the first sign of hypersensitivity or skin rash, discontinue use of this preparation. Particular caution should be employed if areas of involved skin to be treated are denuded or abraded.

FOR EXTERNAL USE ONLY. Keep away from eyes. KEEP OUT OF REACH OF CHILDREN. Contents under pressure. Do not puncture or incinerate container. Do not expose to temperatures above 120°F (49°C).